Mirum Pharmaceuticals, Inc.
NASDAQ:MIRMBiotechnology
+$3.89 today
- Market cap
- $6.04B
- Beta
- 0.51
- P/E (TTM)
- -7.8
- EPS (TTM)
- -$13.57
Volume 0.50M
Average 0.95M
MIRM Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Mirum Pharmaceuticals, Inc.NASDAQ: MIRM
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development growth accelerates
Q2 FY2026 research & development of $90.53M rose 96.5% year over year, ahead of the +68.3% change in trailing-twelve-month research & development. Sequentially, it fell 7.5% from the prior quarter. Over 3 fiscal years it compounded at +20.3% a year.
Context
- Research & development amounted to 35.7% of revenue in FY2025, down 6.0 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +96.5% holds above the trailing-twelve-month pace of +68.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 186.18M USD
- Year-over-year change
- +32.4%
- 4-year CAGR
- +9.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 186.18M | +32.4% |
| FY2024 | 2024-12-31 | 140.63M | +37.1% |
| FY2023 | 2023-12-31 | 102.61M | -4.0% |
| FY2022 | 2022-12-31 | 106.84M | -18.7% |
| FY2021 | 2021-12-31 | 131.43M | — |
Research & Development vs competitors
How MIRM compares with its peers on the latest reported figures
- MIRM's LTM Jun 2026 research & development of $282.51M is the 4th highest of the 8 companies compared; the peer median is $245.55M.
- Its year-over-year change of +68.3% is the 2nd highest of 8, against a peer median of +12.5%.
- Research & development amounts to 45.7% of revenue for MIRM, versus a peer median of 131.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $770.95M | +12.5% | +2.0% | 115.2% | |
| LTM Jun 2026 | $490.14M | +154.4% | +16.5% | 38.2% | |
| LTM Mar 2026 | $342.68M | +13.3% | +6.1% | 518.8% | |
| LTM Jun 2026 | $282.51M | +68.3% | +20.3% | 45.7% | |
| LTM Sep 2026 | $245.55M | +16.8% | -3.2% | 37.7% | |
| LTM Mar 2026 | $98.25M | -44.3% | -8.8% | 216.6% | |
| LTM Mar 2026 | $91.32M | -20.8% | -13.4% | 131.9% | |
| LTM Mar 2026 | $66.77M | -12.8% | -2.0% | 185483.3% | |
| Peer median (excluding MIRM) | $245.55M | +12.5% | -2.0% | 131.9% | |
Competitors are the stored peer set for MIRM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 19.14M | 77.06M | 186.37M | 336.89M | 521.31M |
| Cost of Revenue | 1.9M | 12.37M | 47.04M | 81.64M | 100.58M |
| Gross Profit | 17.24M | 64.69M | 139.34M | 255.25M | 420.73M |
| Gross Margin | 90.1% | 83.9% | 74.8% | 75.8% | 80.7% |
| Research & Development | 131.43M | 106.84M | 102.61M | 140.63M | 186.18M |
| Selling, General & Admin | 59.22M | 89.07M | 145.88M | 202.22M | 257.03M |
| Operating Expenses | 190.65M | 195.91M | 248.49M | 342.85M | 443.21M |
| Depreciation & Amortization | 975K | 3.24M | 10.83M | 23.63M | 24.24M |
| EBITDA | (65.39M) | (122.85M) | (136.49M) | (48.97M) | 17.21M |
| EBITDA Margin | -341.7% | -159.4% | -73.2% | -14.5% | 3.3% |
| Operating Income | (173.41M) | (131.22M) | (109.15M) | (87.61M) | (22.14M) |
| Operating Margin | -906.1% | -170.3% | -58.6% | -26.0% | -4.2% |
| Interest Income | 366K | 3.86M | 13.74M | 13.79M | 12.73M |
| Interest Expense | 17.59M | 15.98M | 15.11M | 14.31M | 14.39M |
| Other Income / Expenses | 89.46M | (10.85M) | (53.27M) | 694K | 709K |
| Income Before Tax | (83.95M) | (142.07M) | (162.42M) | (86.91M) | (21.43M) |
| Pre-Tax Margin | -438.7% | -184.4% | -87.1% | -25.8% | -4.1% |
| Income Tax Expense | 37K | (6.41M) | 991K | 1.03M | 1.94M |
| Net Income | (83.99M) | (135.67M) | (163.42M) | (87.94M) | (23.36M) |
| Net Margin | -438.9% | -176.0% | -87.7% | -26.1% | -4.5% |
| EPS (Basic) | (2.77) | (4.01) | (4.00) | (1.85) | (0.47) |
| EPS (Diluted) | (2.77) | (4.02) | (4.00) | (1.85) | (0.47) |
| Weighted Avg Shares | 30.32M | 33.84M | 40.89M | 47.52M | 50.2M |
| Weighted Avg Shares (Diluted) | 30.32M | 33.98M | 40.89M | 47.52M | 50.2M |
Mirum Pharmaceuticals, Inc.
NASDAQ:MIRM
Intrinsic Alpha fair value
Locked
Current Price
$92.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.